DC
BTAI icon

Davenport & Co’s BioXcel Therapeutics BTAI Stock Holding History

Davenport & Co’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-738
Closed -$4.42K – 1175
2024
Q4 		$4.42K Sell
738
-315
-30% -$2.63K ﹤0.01% 1148
2024
Q3 		$10.3K Sell
1,053
-272
-21% -$3.65K ﹤0.01% 1139
2024
Q2 		$27.1K Sell
1,325
-824
-38% -$27.6K ﹤0.01% 1108
2024
Q1 		$97K Sell
2,149
-63
-3% -$3K ﹤0.01% 1093
2023
Q4 		$104K Sell
2,212
-1,632
-42% -$90.7K ﹤0.01% 1046
2023
Q3 		$156K Buy
3,844
+112
+3% +$11.3K ﹤0.01% 1012
2023
Q2 		$398K Sell
3,732
-1,286
-26% -$428K ﹤0.01% 805
2023
Q1 		$1.5M Sell
5,018
-4,801
-49% -$2.05M 0.01% 436
2022
Q4 		$3.38M Buy
9,819
+3,035
+45% +$734K 0.03% 301
2022
Q3 		$1.28M Buy
6,784
+1,430
+27% +$332K 0.01% 439
2022
Q2 		$1.13M Buy
5,354
+3,249
+154% +$683K 0.01% 471
2022
Q1 		$704K Sell
2,105
-63
-3% -$18.3K ﹤0.01% 639
2021
Q4 		$705K Buy
2,168
+757
+54% +$325K ﹤0.01% 663
2021
Q3 		$685K Buy
1,411
+541
+62% +$238K ﹤0.01% 636
2021
Q2 		$405K Sell
870
-639
-42% -$348K ﹤0.01% 709
2021
Q1 		$1.04M Buy
1,509
+1,065
+240% +$857K 0.01% 387
2020
Q4 		$328K Buy
+444
New +$346K ﹤0.01% 622

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Davenport & Co's BTAI Position: Q1 2025 in Review

Davenport & Co sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 738 shares — an estimated $4.42K sold.

Davenport & Co first reported a position in BTAI in Q4 2020 and held it in 17 quarters. The position peaked at $3.38M in Q4 2022. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Davenport & Co reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Davenport & Co sold 738 BioXcel Therapeutics shares in Q1 2025, an estimated $4.42K.
  • Davenport & Co first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 17 quarters.
  • Davenport & Co's BioXcel Therapeutics position peaked at $3.38M in Q4 2022.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Davenport & Co's 13F filing for Q1 2025, filed 28 Apr 2025.